Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia.
Császár
A
A
3rd Department Semmelweis Medical University, Budapest.
Karádi
I
I
Köszegi
G
G
Pados
G
G
Németh-Csóka
M
M
Pichler
M
M
Romics
L
L
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001629:Bezafibrate / Q000008:administration & dosage*; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000201:enzymology; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003692:Delayed-Action Preparations; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D000469:Alkaline Phosphatase; D001629:Bezafibrate